Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Are Things Now Getting Personal?

Affiliations

¹ Division of Hematology/Oncology, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: matthew.galsky@mssm.edu.
² Departments of Medicine and Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
³ Department of Population Health Science and Policy, Institute for Healthcare Delivery Science, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Editorial

Matthew D Galsky et al. Eur Urol. 2017 Oct.

. 2017 Oct;72(4):555-556.

doi: 10.1016/j.eururo.2017.04.012. Epub 2017 Apr 19.

¹ Division of Hematology/Oncology, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: matthew.galsky@mssm.edu.
² Departments of Medicine and Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
³ Department of Population Health Science and Policy, Institute for Healthcare Delivery Science, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

No abstract available

Comment on

Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy.
Seiler R, Ashab HAD, Erho N, van Rhijn BWG, Winters B, Douglas J, Van Kessel KE, Fransen van de Putte EE, Sommerlad M, Wang NQ, Choeurng V, Gibb EA, Palmer-Aronsten B, Lam LL, Buerki C, Davicioni E, Sjödahl G, Kardos J, Hoadley KA, Lerner SP, McConkey DJ, Choi W, Kim WY, Kiss B, Thalmann GN, Todenhöfer T, Crabb SJ, North S, Zwarthoff EC, Boormans JL, Wright J, Dall'Era M, van der Heijden MS, Black PC. Seiler R, et al. Eur Urol. 2017 Oct;72(4):544-554. doi: 10.1016/j.eururo.2017.03.030. Epub 2017 Apr 5. Eur Urol. 2017. PMID: 28390739